W
Walter Berger
Researcher at Medical University of Vienna
Publications - 396
Citations - 16667
Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
P18.06.B ETS-Transcription Factor inhibitors are effective inTERT promoter mutated meningioma cells in vitro
Katharina Neumayer,Lucia Kastler,Magdalena Laaber,Cornelia Roschger,Stefan Lenz,Daniela Lötsch-Gojo,Walter Berger,and Harry E. Gruber,Sabine Spiegl-Kreinecker +8 more
TL;DR: It is indicated that ETS transcription factor inhibition by TK216 exerts antitumour activity in the authors' TERT promoter mutant meningioma cell model and may represent a promising new therapeutic option for patients with aggressive, Tert promoter mutated meningIoma.
Journal ArticleDOI
HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations
Anna Laemmerer,Dominik Kirchhofer,Sibylle Madlener,Daniela Loetsch-Gojo,C. Jaunecker,Lisa Gabler,Lisa Mayr,Natalia Stepien,Alicia Baumgartner,Karin Dieckmann,Stefan M. Pfister,Marcel Kool,Sonja Krausert,Apurva Gopisetty,Natalie Jäger,Andreas Peyrl,Amedeo A. Azizi,Walter Berger,Johannes Gojo +18 more
TL;DR: ParPi combinations show potential for the treatment of pHGG with ATRX mutations, with strong synergistic effects on cell viability, which was not observed to a comparable extent in other models such as BRAFV600E/TERT promotor mutant pHGG.
Journal ArticleDOI
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Monika Caban,Diana Groza,Hemma Schueffl,Alessio Terenzi,Alexander Tolios,Thomas Mohr,Marlene Mathuber,Kushtrim Kryeziu,C. Jaunecker,Christine Pirker,Bernhard K. Keppler,Walter Berger,Christian R. Kowol,Petra Heffeter +13 more
TL;DR: In this article , a hypoxia-activatable Co(III)-based prodrug (KP2334) was recently synthesized releasing the new EGFR inhibitor KP2187 in a highly tumor-specific manner only in hypoxic areas of the tumor.
Journal ArticleDOI
Hgg-08. combinatorial activity of cdk4/6-inhibitors and trametinib in pediatric high-grade glioma with brafv600e mutation and homozygous cdkn2a deletion
Lisa Mayr,Lisa Gabler,Sibylle Madlener,Julia M. Berger,Dominik Kirchhofer,Anna Lämmerer,Katharina Bruckner,Daniela Lötsch,Walter Berger,Johannes Gojo +9 more
TL;DR: In this paper , the authors investigated CDK4/6 inhibitors alone and in combination with trametinib in HGG cell models with BRAFV600E mutation and homozygous CDKN2A deletion.
Journal ArticleDOI
Combination of Drug Delivery Properties of PAMAM Dendrimers and Cytotoxicity of Platinum(IV) Complexes—A More Selective Anticancer Treatment?
Michaela Hejl,Petra Vician,Michael A. Jakupec,Walter Berger,M. S. Galanski,Bernhard K. Keppler +5 more
TL;DR: In this article, the authors combined PAMAM dendrimers with various platinum(IV) complexes in order to provide an improved approach of anticancer treatment, showing a faster reduction of conjugates.